Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia (2024) Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, et al. Journal article, Letter Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries (2024) Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, et al. Journal article Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. (2024) Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, et al. Journal article Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry (2024) Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, et al. Journal article Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms (2024) Winter S, Schneider M, Oelschlaegel U, Maggioni G, Riva E, Raddi MG, Bencini S, et al. Journal article Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma (2023) Leipold AM, Werner RA, Duell J, Jung P, John M, Stanojkovska E, Zhou X, et al. Journal article Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations (2023) Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, et al. Journal article, Review article Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification (2023) Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, et al. Journal article A C/ebpα isoform specific differentiation program in immortalized myelocytes (2023) Garcia-Cuellar MP, Akan S, Slany R Journal article Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia (2023) Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, et al. Journal article